Compare ZSQR & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZSQR | IKT |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 220.5M |
| IPO Year | 2020 | 2020 |
| Metric | ZSQR | IKT |
|---|---|---|
| Price | $3.91 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 375.9K | 368.1K |
| Earning Date | 08-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.27 | ★ 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,363,045.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $1.33 |
| 52 Week High | $16.62 | $2.61 |
| Indicator | ZSQR | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 34.98 |
| Support Level | $2.81 | $1.59 |
| Resistance Level | $4.64 | $2.13 |
| Average True Range (ATR) | 0.47 | 0.10 |
| MACD | 0.26 | -0.03 |
| Stochastic Oscillator | 79.36 | 22.89 |
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.